🇺🇸 FDA
Patent

US 9206257

Human monoclonal antibodies specific for glypican-3 and use thereof

granted A61KA61K2039/505A61K39/39558

Quick answer

US patent 9206257 (Human monoclonal antibodies specific for glypican-3 and use thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/505, A61K39/39558, A61K47/6813, A61K47/6829